Q-omics provides the consensus-scored GAPLINC profile across patient tissues and cancer cell-line models. GAPLINC expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GAPLINC is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, GAPLINC RNA expression shows 15,879 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where GAPLINC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPLINC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPLINC survival associations across molecular data types. GAPLINC RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPLINC RNA expression–survival associations across cancer types. High GAPLINC expression shows unfavorable associations in UVM, ACC, OV, LUSC and KIRP, but favorable associations in DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GAPLINC RNA expression.
This table summarizes GAPLINC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPLINC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPLINC shows higher tumor expression in HNSC, THCA, KIRC, LIHC, STAD and COAD. The HNSC box plot shows higher GAPLINC RNA expression in tumor versus normal tissue (log2 FC = +0.548, t-test p < 0.001).
This table shows molecular features associated with GAPLINC in patient tissues and cancer cell lines. In patient samples, GAPLINC shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
